Scarica l'app Stockscreener
96.95
1.65%
1.57
Dopo l'orario di chiusura:
96.95
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché RVTY Giù?
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Revvity Inc Borsa (RVTY) Ultime notizie
Revvity stock: Analyst estimates & ratings - MSN
Revvity stock (US76155R1086): cancer test launch and steady demand keep diagnostics group in focus - AD HOC NEWS
Revvity declares $0.07 dividend - MSN
Revvity Inc. stock outperforms competitors on strong trading day - MarketWatch
Revvity Stock: Analyst Estimates & Ratings - inkl
Revvity stock (US76155R1086): diagnostics specialist in focus after latest earnings and life-science - AD HOC NEWS
Revvity Inc. stock underperforms Wednesday when compared to competitors - MarketWatch
Revvity Inc. stock (US76155R1086): investors weigh latest earnings and diagnostics focus - AD HOC NEWS
There May Be Some Bright Spots In Revvity's (NYSE:RVTY) Earnings - 富途牛牛
Revvity's (NYSE:RVTY) Conservative Accounting Might Explain Soft Earnings - Yahoo Finance
Revvity stock (US76155R1086): Q1 earnings beat and guidance set the tone - AD HOC NEWS
Revvity (RVTY) Is Down 5.0% After Raising 2026 Outlook And Securing FDA Assay Clearance - Sahm
Revvity stock (US76155R1086): FDA assay clearance, outlook to 2026 and fresh collaboration momentum - AD HOC NEWS
Can Revvity Expand Diagnostics Across the S&P 500 Index? - Kalkine Media
Revvity, Inc. (RVTY): Investor Outlook Reveals 20.94% Potential Upside In Healthcare Innovation - DirectorsTalk Interviews
Revvity stock (US76155R1086): steady diagnostics player after latest quarterly update - AD HOC NEWS
RVTY expands endocrine diagnostics with FDA-cleared testosterone assay - MSN
Revvity stock (US76155R1086): collaboration momentum and diagnostics focus after recent share move - AD HOC NEWS
Revvity Inc. stock underperforms Friday when compared to competitors - MarketWatch
Revvity stock (US76155R1086): T. Rowe Price reports a 9% stake - AD HOC NEWS
FDA OKs Revvity’s Total Testosterone Assay - Medical Product Outsourcing
T. Rowe Price (RVTY) discloses 10.1M-share, 9.0% stake in Revvity - Stock Titan
(RVTY) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily
The Top 5 Analyst Questions From Revvity’s Q1 Earnings Call - Yahoo Finance
Analysts Conflicted on These Healthcare Names: Cullinan Management (CGEM), Humacyte (HUMA) and Revvity (RVTY) - The Globe and Mail
Revvity stock (US76155R1086): Q1 earnings beat with $1.06 EPS - AD HOC NEWS
RVTY Expands Endocrine Diagnostics With FDA-Cleared Testosterone Assay - The Globe and Mail
BofA Securities Maintains Revvity(RVTY.US) With Hold Rating - Moomoo
Is Revvity stock underperforming the S&P 500? - MSN
Is Revvity Inc (RVTY) a Bargain After 4.3% Drop? GF Value Says U - GuruFocus
Is Revvity Inc (RVTY) a Bargain After 4.3% Drop? GF Value Says Undervalued - GuruFocus
Revvity stock (US76155R1086): FDA clearance for testosterone assay, Q1 earnings beat - AD HOC NEWS
Transcript : Revvity, Inc. Presents at Bank of America Global Healthcare Conference 2026, May-13-2026 09 - marketscreener.com
FDA Clears Revvity Total Testosterone Assay for Automated Testing - Clinical Lab Products
Revvity Receives FDA Clearance for Total Testosterone Assay Enabling Comprehensive Automated Testosterone Testing Solution - Yahoo Finance
Revvity (RVTY) grows Q1 2026 sales to $711M while margins tighten - Stock Titan
Revvity stock (US76155R1086): Q1 earnings beat and analyst upgrade drive gains - AD HOC NEWS
Revvity (NYSE:RVTY) Stock Acquired Rep. Gilbert Ray Cisneros, Jr. - MarketBeat
Revvity Inc. stock outperforms competitors despite losses on the day - MarketWatch
Revvity (RVTY) director Alexis Michas receives stock awards and reports indirect holdings - Stock Titan
REVVITY (RVTY) director granted new restricted stock unit awards - Stock Titan
Revvity (RVTY) director Michael Klobuchar receives new restricted stock unit grants - Stock Titan
Revvity (RVTY) director Frank Witney granted restricted stock unit awards - Stock Titan
Director Samuel R. Chapin receives stock awards at REVVITY (RVTY) with RSUs vesting in 2027 - Stock Titan
Revvity (RVTY) director Michel Vounatsos receives new restricted stock units - Stock Titan
Revvity (RVTY) director Michelle McMurry-Heath granted new RSU awards - Stock Titan
Equity grants add 2,280 shares to Revvity (RVTY) director’s stake - Stock Titan
Revvity (RVTY) Q1 2026 Earnings Transcript - AOL.com
Revvity stock (US76155R1086): Q1 beat and analyst upgrade spark gains - AD HOC NEWS
Mitsubishi UFJ Asset Management Co. Ltd. Trims Stake in Revvity Inc. $RVTY - MarketBeat
Revvity earnings: What to look for from RVTY - MSN
Revvity outlines 3%-4% 2026 organic growth and $5.20-$5.30 EPS while planning China immunodiagnostics divestiture - MSN
Revvity Inc. stock (US76155R1086): Barclays lifts price target as Q1 beats estimates - AD HOC NEWS
Revvity, Inc. (NYSE:RVTY) First-Quarter Results Just Came Out: Here's What Analysts Are Forecasting For This Year - 富途牛牛
Revvity, Inc. (NYSE:RVTY) Just Reported First-Quarter Earnings: Have Analysts Changed Their Mind On The Stock? - simplywall.st
RVTY Maintained by Barclays -- Price Target Raised to $105 - GuruFocus
0.72%
0.29%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):